DB00216 Pfizer . Pfizer has developed and launched eletriptan , a P28222 /1D agonist , for the potential treatment of migraine with and without aura . DB00216 has 6-fold greater affinity for the P28221 receptor than sumatriptan , and a 3-fold greater affinity for the P28222 receptor [ 249570 ] . DB00216 pharmacology has also been evaluated in vitro in comparison with zolmitriptan ( AstraZeneca plc ) and naratriptan ( GlaxoSmithKline plc ) [ 290116 ] .